



Samford University
McWhorter School of Pharmacy

NEW DRUG UPDATE

CONTINUING PHARMACY EDUCATION (CPE) ACTIVITY

Date: Sunday, December 7, 2025
Time: 1:00 PM – 4:15 PM
Location: Samford University College of Health Sciences (CHS) 1409

Activity Description: This knowledge-based continuing pharmacy education (CPE) activity focusing on New Drug Update is approved for 3 live contact hours (0.3 CEUs). It is intended and appropriate for all pharmacists. To receive credit, participants must attend the entire session and complete activity assessments. Credit will be sent electronically through CPE Monitor within 30 days following the program. NABP e-Profile ID# and Date of Birth (mmdd) required.

STATEMENT OF EDUCATIONAL NEED

So far in 2025, there have been 32 new drug approvals by the FDA. This means that novel treatment options are available for patients that may substantially improve public health. From drugs that treat metastatic breast cancer to drugs that treat moderate to severe pain, the new drugs introduced to the market will likely have a profound impact on a wide range of diseases. To be relevant practitioners, pharmacists and pharmacy technicians need to have a thorough understanding of the newly approved medications. The purpose of this knowledge-based activity is to educate pharmacists and pharmacy technicians on some of the recently approved drugs of 2025. More specifically, there will be information provided on the mechanism of action, effectiveness, safety, and handling of newly approved drugs.

Source(s):

- Novel Drug Approvals for 2025. U.S. Food and Drug Administration. <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025>. Published 10/01/24. Accessed October 3, 2025.
- New Drug Approvals <https://www.drugs.com/newdrugs.html> Published 2025. Accessed October 3, 2025.

Activity Faculty:

David R. Luthin, PhD

Professor

Samford McWhorter School of Pharmacy

Jennifer Beall, PharmD, MSN, BCPS, CHSE

Professor and Director of Pharmacy Labs and Simulation Experiences

Samford McWhorter School of Pharmacy

***Speakers have no relevant conflicts of interests to disclose.**

Activity Learning Objectives:

After this session, the participant should be able to:

Pharmacists

- Identify the Food and Drug Administration (FDA) therapeutic indications for newly approved drugs in 2025
- Describe the correct mechanism of action associated with each new drug.
- Summarize relevant pharmacokinetic parameters and common adverse effects associated with each new drug.
- List appropriate clinical monitoring parameters for each new drug.
- Explain how to appropriately counsel a patient on each new drug.
- Discuss the impact on clinical practice for each new drug.

Technicians

- Recall the disease states treated by new FDA-approved drugs for 2024.
- Identify common dosage formulations associated with each new drug.
- List common treatment doses for each new drug.
- Identify which new drugs require unique storage conditions.
- Describe the major adverse drug effects associated with each new drug.

Activity Schedule:

12:30 P.M.:	Sign In/Registration
1:00 – 2:30 P.M.:	The Science Behind New Drugs Approved in 2025
2:30 – 2:45 P.M.:	Break
2:45 – 4:15 P.M.:	The Clinical Impact of New Drugs Approved in 2025
4:15 P.M.:	Dismiss

Activity Cost:

Activity Cost:

Pharmacists - \$90 (\$100 at the door)

Pharmacy technician - \$35 (\$45 at the door)

****Registration:** For online registration go to: <http://www.samford.edu/pharmacy/continuing-education>

ACPE UAN #: 0002-0000-25-012-L01-P

0002-0000-25-012-L01-T



Samford University McWhorter School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This ACPE-accredited CPE activity is conducted without commercial support or influence of any kind.